The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-101, a CAR T-cell therapy being developed by Mustang Bio to…
News
Corcept Therapeutics has asked the U.S. Food and Drug Administration (FDA) to approve relacorilant, to be used in combination with the standard chemotherapy agent…
The U.S. Food and Drug Administration (FDA) has approved label updates for two Bristol Myers Squibb (BMS) CAR T-cell therapies, both for the treatment…
The U.S. Food and Drug Administration (FDA) has agreed to review an application for oral Inqovi (decitabine and cedazuridine) in combination with oral venetoclax for…
Daraxonrasib, Revolution Medicines’ RAS inhibitor candidate for the treatment of people with advanced, or metastatic, pancreatic cancer with KRAS G12 mutations, has been…
July 16 marks Glioblastoma Awareness Day (GBM Day), an annual observance dedicated to raising awareness about the rare and aggressive form of brain cancer, promoting…
A Phase 1 clinical trial evaluating escalating doses of Anixa Biosciences’ experimental CAR T-cell therapy for recurrent ovarian cancer has begun dosing participants…
Linvoseltamab, now branded as Lynozyfic, has received accelerated approval from the U.S. Food and Drug Administration (FDA) for treating adults with relapsed or refractory…
Senti Biosciences‘ experimental cell therapy SENTI-202 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) as a potential therapy…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GLIX1, a cancer treatment now in the preclinical stages of development, as…
